WO1990010385A1

WO1990010385A1 - Cd8-based pharmaceuticals

Info

Publication number: WO1990010385A1
Application number: PCT/US1990/001393
Authority: WO
Inventors: Mark L. Tykocinski; David R. Kaplan
Original assignee: Tykocinski Mark L; Kaplan David R
Priority date: 1989-03-15
Filing date: 1990-03-14
Publication date: 1990-09-20
Also published as: AU5342290A; US5623056A; EP0463080A1; CA2050346A1; EP0463080A4; JPH04506061A

Abstract

The inhibitory ligand function of the T lymphocyte-associated peptide CD8 is disclosed, enabling the development of CD8-based peptide pharmaceuticals. Specific and nonspecific immunomodulation, enhancement of cellular engraftment, and modulation of nonimmune cells are achieved by using various membrane-binding and soluble CD8 peptides and biomembranes, such as cells and liposomes, bearing CD8 peptides. Methods for producing useful CD8 peptides, including glycoinositolphospholipid-modified CD8 and CD8:ligand conjugates, via recombinant DNA techniques, are also disclosed.

Description

CD8-Based Pharmaceuticals

Technical Field

The present invention relates to immunomodulation for the treatment of subjects in need of the abrogation of untoward immunological reactivities and of subjects in need of the enhancement of cell, tissue and organ transplant survival. More particularly, it relates to the use of CD8 (hereinafter defined) and its derivatives as immunomodulators to effect said therapeutic objectives. The present invention also relates to broader therapeutic uses for CDβ's newly discovered inhibitory ligand activity in the modulation of cells outside of the immune system.

Background Art

CD8 is a glycoprotein produced in cell surface-associated and soluble forms by subsets of thymic and peripheral T lymphocytes. CD8-positivity defines the subset of mature T lymphocytes in the periphery that mediate class I major histocompatibility complex (MHC)-restricted cytotoxicity against virally-infected, allogeneic and other cellular targets. The only known function for CD8, prior to the disclosure of the present invention, was its molecular accessory function in such CD8-positive cytotoxic T lymphocytes. According to this molecular accessory function, encompassing receptor-like and adhesin-like activities, CD8 plays an obligatory role in T cell activation and triggering of cytotoxicity through the T cell receptor complex. In addition to cytotoxicity triggered by antigen recognition, T lymphocytes with a CD8-positive phenotype are known to mediate other effector functions including an array of regulatory activities in the immune system. The molecular explanation for the various immuno- regulatory phenomena that have been described for such cells has for a long time remained elusive. In the present invention, we disclose that the CD8 molecule is a critical molecular determinant in the immunoregu- latory activity mediated by CD8-positive lymphocytes. This ensues from the discovery that CD8 can function as an inhibitory ligand, and more specifically, that the CD8 molecule inhibits immune and other cells that are being costimulated with certain secondary molecules (hereinafter referred to as "ligands"; vide infra). In turn, the insight into CD8'ε inhibitory ligand function enables the use of CD8 as a pharmaceutical for modulation of immune and nonimmune cells. Hence, in the present invention, antigen-specific (hereinafter referred to as "specific") immunotolerization in subjects in need of the selective suppression of immune responses to defined antigens is achieved through the pharma¬ ceutical use of CD8, and derivatives thereof. The discovery of CD8's inhibitory ligand activity was facilitated by recent technological advances made by the present inventors in the fields of gene transfection and protein engineering in human hematopoietic cells. At the present time, specific iπππunotolerization therapies, primari¬ ly centered around the administration of specific antigen in association with additional substances, are relatively ineffective. Therapies for transplant, allergic and other subjects in need of immunosuppression most commonly employ generalized, nonspecific immunosuppressive agents. These therapeutic agents, which include X-irradiation, cytotoxic drugs, cyclosporin A, corticosteroids, and antilymphocytic serum, suffer from significant side effects involving multiple immune and nonimmune organs. Furthermore, in the case of clinical transplantation, no effective strategies for biochemically altering grafts in vitro to prolong their survival in a host have been described.

Limitations in the field of immunomodulation have largely been a consequence of lack of insights into the precise molecular factors that mediate natural immunoregulation. The insight into CD8's critical role as an immunoregulatory molecule provides, for the first time, a chem- ically defined, cloned factor for artificial immunomodulation in vivo and in vitro. Its availability in cloned form offers opportunities to provide significant amounts of the material for use in therapy and to make programmed modifications to improve activity.

An object of the present invention is to provide an effective pro- cess for specific immunomodulation, which process comprises the use of CD8 compositions.

Another object of the present invention is to provide a process, using CD8 compositions, for generalized, nonspecific immunosuppression, which process suffers from fewer side effects than currently available processes, and permits more specific targeting of organs of the immune system than current therapies.

Yet another object of the present invention is to provide a process for biochemically altering grafts prior to transplantation, in a way which enables them to evade immunological rejection mechanisms, and thereby promote their engraftment, which process comprises the use of CD8 compositions.

Still another object of the present invention is to provide a pro¬ cess for prevention of graft versus host disease following bone marrow transplantation, which process comprises the use of CD8 compositions.

Still another object of the present invention is to provide a process for selective modulation of nonimmune cells, which process comprises the use of CD8 compositions.

Still another object of the present invention is to provide a process for producing CD8 compositions using recombinant DNA techniques.

Other objectives, features and advantages of the invention will be found throughout the following description and claims.

Disclosure of Invention

According to the present invention, there are provided compositions comprising membrane-binding and soluble CD8 peptides, including those genetically engineered, and methods of use for immunomodulation and modulation of nonimmune cells in vivo and in vitro. A pharmacologically active CD8 composition comprises a natural CD8 peptide, or a CD8 peptide derivative having an amino acid sequence sufficiently duplicative of that of natural CD8 to allow possession of inhibitory ligand activity, associated with one or more secondary ligands that serve to direct CDβ's inhibitory ligand activity to specific target cells. This association between a CD8 peptide and a secondary ligand can be noncovalent and ensue simply from their presence on a common biomembrane (of a cell, liposome, planar membrane, pseudocyte, etc.), or covalent, through linkage in a CD8:ligand conjugate as part of a linear or branched poly- peptide chimera. CD8 peptides can be expressed on cellular membranes by transfecting into host cells suitable DNA sequences encoding said CD8 peptides, by exogenously incorporating into the cellular membrane glycoinositolphospholipid-modified CD8 peptide derivatives, or by bind¬ ing CD8:ligand peptides to membrane receptors with specific affinity for the ligand component. A broad array of CD8:ligand combinations can be used, each of which permits the targeting of CD8'ε modulatory activity to a specific subset of cells. A preferred embodiment of the present invention, particularly applicable for the purpose of specific T cell immunotolerization, comprises a CD8 composition in which a natural CD8 peptide, or a CD8 peptide derivative retaining inhibitory ligand activity, is associated with a peptide derivative of a major histo- compatibility complex (MHC) protein. A defined nominal antigen peptide (NAP) can be secondarily associated with the MHC component of said composition to permit the induction of specific immunotolerance for the parental protein encompassing said NAP sequence. Another preferred embodiment of the present invention, particularly applicable for treating immunoglobulin E (IgE)-related allergic disorders, comprises a soluble CD8:Fcε conjugate wherein CD8, or a CD8 peptide derivative retaining inhibitory ligand activity, is covalently linked to an IgE Fc domain and used to coat Fcε receptor-bearing cells. Yet another pre- ferred embodiment of the present invention, particularly applicable for the purpose of generalized, nonspecific immunosuppression, comprises a soluble CD8:Fc conjugate, wherein CD8, or a CD8 peptide derivative retaining inhibitory ligand activity, is covalently linked to an immuno¬ globulin (non-IgE) Fc domain. This CD8:Fc conjugate can be used to coat Fc receptor (FcR)-bearing antigen presenting cells, and these cells, in turn, can be used to inhibit immune cells in a nonspecific fashion. Still another preferred embodiment of the present invention, particular¬ ly applicable for the purpose of prolongation of graft survival in a transplant recipient, comprises a process wherein a membrane-binding CD8 peptide is used to coat graft cells prior to transplantation, to promote engraftment in a transplant recipient. Still another preferred embodi¬ ment of the present invention, particularly applicable for the purpose of prevention of graft versus host disease following bone marrow transplantation, comprises a process wherein a therapeutic biomembrane preparation comprising a CD8 peptide and a MHC peptide corresponding to the transplant recipient's haplotype, or a CD8:MHC conjugate, is used to treat bone marrow cells in vitro prior to transplantation, to inhibit alloreactive immune cells in the donor cell population.

Best Modes for Carrying Out the Invention The present invention is directed to methods for cellular modula¬ tion, with a focus on cells of the immune system. The compositions and methods for specific immunomodulation and generalized, nonspecific immunosuppression are applicable to, but not restricted to, the clinical settings of transplantation and autoimmune, hypersenεitivity, allergic and other immunological disorders.

The present invention resides in the discovery, as disclosed by us in U.S. Pat. Ser. Nos. 07/323,770 and 07/429,401, that the CD8 molecule can function as an inhibitory ligand, and in turn, can be utilized therapeutically in novel ways as an immunomodulatory pharmaceutical. The inventors of the present invention previously developed a methodology for stable gene transfer into nontransformed, cloned human T cells (Proc. Natl. Acad. Sci. U.S.A. 85:4010-4014, 1988). This methodology, in turn, enabled the first linking of antisense mutagenesis and T cell cloning technologies. When applied to CD8, in earlier studies, to create T cell clonal phenocopies of null mutations for CD8, this transfection technol¬ ogy permitted a definitive demonstration of CD8's function as an obliga¬ tory accessory molecule for the specific activation and killing mediated by CD8-positive cytotoxic T cells (J. Exp. Med. 168: 1237-1245, 1988). Another byproduct of our transfection technology, and specifically of our ability to produce CD8-negative antisense mutants, is the insight into CDβ's previously unsuspected role in the immunoregulation mediated by CD8-positive T cells, as disclosed in the present invention. Specifically, we have established that a natural or genetically engineered CD8 peptide can inhibit T cells and other cells when said CD8 peptide is associated with a second ligand that would otherwise, i.e., in the absence of CD8 peptide, function as a cellular activator. For instance, in the case of T cells, the second ligand can be an allo-MHC molecule or a specific (processed) antigen associated with a self-MHC molecule. CDβ's immunomodulatory activity has been assessed experi¬ mentally by our group using several types of in vitro cellular prolif¬ eration and cytotoxicity assays, employing a variety of sense and antisense CD8 transfectants and controls. Cells for these studies were obtained from subjects JH (HLA haplotype:A2,3;B7,44;DR2,4), DK (HLA haplotype A2,24;B13,50;DR2,7), and MW (HLA haplotype Al,31;B8;DR3). Our findings include the following:

(i) The proliferative response of responding cells to irradiated, allogeneic stimulator cells in mixed cell cultures is dependent upon the absence of CD8 on the irradiated stimulators. In one such experiment, 10 responder peripheral blood mononuclear cells (PBMC) from DK were combined with stimulators comprising either 2 x 10⁴ irradiated (5000 R), syngeneic cells of the cloned, CD8-positive T cell line JH.ARL.l (de¬ rived from JH and with known allospecificity for HLA-B35) or 2 x 10⁴ irradiated (5000 R), CD8-negative antisense CD8 transfectant derivatives of the JH.ARL.l line, in quadruplicate wells of a 96-well flat-bottom microtiter plate in RPMI 1640 medium with 10% fetal bovine sera. Cells were cocultured for 4-7 days at 37°C, adding 1 μd of [³H]-thymidine to each well during the last 18 h. The cells were harvested, and the radioactivity incorporated was counted. A proliferative response was observed for the CD8-negative, but not for the CD8-positive, stimulator at all time-points. This was confirmed using a sense, instead of an antisense, transfection approach. In one such experiment, 10⁵ responder PBMC from MW were combined with stimulators comprising either 2 x 10 irradiated (15,000 R), nontransfected K562 human eyrthroleukemia cells or K562 cells transfected with an irrelevant expression construct, both of which are CD8-negative, or 2 x 10⁴ irradiated (15,000 R) sense CD8 K562 transfectants (CD8-positive) in the proliferation assay as described. Again, only the CD8-negative, but not CD8-positive, cells were able to stimulate proliferation. Similar results were obtained when either JY (human EBV-immortalized B) or KM-102 (human SV-40 large T-immortalized bone marrow stromal) cells were used in place of K562 cells as (non-T cell) stimulators, firmly establishing the generality of CD8-dependent inhibition.

(ii) The proliferative response of responding cells to irradiated, allogeneic stimulator cells and their capacity for cytotoxicity against allogeneic target cells can be inhibited by the simultaneous addition of third party cells, if the latter cells bear both CD8 and a specific alloantigen that is recognized by the responding cells, and thus such cells function in an immunosuppressive "veto-like" capacity (Proc. Natl. Acad. Sci. U.S.A. 86:8512-8515, 1989; published pursuant to filing dates of U.S. Pat. Nos. 07/323,770 and 07/429,401). In one such experiment, 10 responder PBMC from DK were combined with 5 x 10⁴ irradiated (5000 R) stimulator PBMC from JH and varying numbers of cloned T cells as putative inhibitors, originating from JH, comprising either CD8-positive or CD8-negative (antisense) JH.ARL.l transfectants. Inhibition of the proliferative response was observed only for the CD8-positive third party cells, and the potency of the inhibition was demonstrated by the finding of 33% and 78% inhibition at inhibitor:stimulator cell ratios of 1:500 and 1:5, respectively. Absence of inhibition upon combining JH responderε, DK stimulators, and JH cloned (CD8-positive) T cell inhibi¬ tors established that a specific recognition event iε required between responders and CD8-positive inhibitors in order for inhibition to occur. We further demonstrated CD8-dependent inhibition of cytotoxic T cell generation in MLR cultures. Allogeneic cultures were εet up in 24-well plates in a volume of 2 ml of RPMI 1640 containing fetal bovine sera. 10⁶ responder PBMC from MW, 5 x 10⁵ irradiated (5000 R) stimulator PBMC from JH, and 10⁵ irradiated (CD8-positive or CD8-negative antisense phenocopieε) cloned JH.ARL.l cells were added per well. After incuba¬ tion for 6 days at 37°C, cells were harvested, and dead cells removed by histopaque density gradient centrifugation. A [⁵¹Cr]-release assay (Cell. Immunol. 88:193-206, 1984) was performed with EBV-transformed JH (LCL) B lymphocytes as targets. Inhibition was evident only with CD8- positive third party cells, and maximal inhibition was achieved when these cells were added at the initiation of the cultures or by day 2. These findings with JH.ARL.l lymphoid cells as inhibitors were confirmed with non-lymphoid K562 cells as stimulators and inhibitors. In one such experiment, 10⁵ responder PBMC from JH, 5 x 10⁴ irradiated (20,000 R) K562 stimulators, and putative inhibitors, comprising either irradiated CD8-negative K562 cells or CD8-positive sense K562 transfectants were used. Marked CD8-dependent inhibition was observed with as few as 5 x 10² inhibitors. In other experimentε, irradiated (15,000 R) immortal- ized JY B cells or immortalized KM-102 human bone marrow stromal cells were used in place of K562 cells, with analogous results.

(iii) The proliferative response of responding cells to irradiated, allogeneic stimulator cells can be blocked by pretreatment of the re¬ sponding cells with irradiated, or otherwise metabolically inactivated, third party "tolerogenic" cells, if the latter cells bear both CD8 and a specific alloantigen that is recognized by the responding cells. In one such experiment, 10⁵ PBMC responders from JH were incubated with fixed (air-dried, with or without poεt-treatment with 2% paraformaldehyde in phosphate-buffered saline for 2 h at 37°C) CD8-positive or CD8-negative K562 or human bone marrow stromal cell transfectants for 24 h in RPMI 1640 supplemented with 10% fetal bovine sera, in quadruplicate 96-well plates. PBMC so pre-treated were recovered, stimulated with CD8- negative counterparts for 18 h in the presence of 0.5 Ci/well [³H]- thymidine, and [³H]-thymidine incorporation was measured. The data indicated a marked and specific CD8-dependent tolerization amidst the responders, which was evident even when a 24 hour recovery interval was introduced between CD8 pretreatment and reεtimulation with CD8-negative stimulators.

Hence, the inhibition directed by CD8 can be used to induce specific immunotole ance. Moreover, assayε εimilar to the ones described have indicated that CD8-mediated inhibition is applicable for the immunomodulation of reεponseε to specific antigenε other than alloantigens, and can be used to study CD8-dependent modulation of nonimmune cells (vide infra) as well. Further experiments have elucidated the functional requirements for the CD8 ligand itself. Two forms of CD8 are known to be preεent on human T lymphocyte εurfaceε: an α:α homodimer and an a: β heterodimer. CD8α (herein referred to aε "CD8") can function as an inhibitory ligand as a monomer, and hence the CD8β chain is not required for inhibition. CD8β requires CD8α in order to be efficiently expressed on the cell surface in native cellular settingε. The CD8 peptide need not be expressed on immune cells per se, and hence T cell-specific factors are not required for CD8-mediated inhibition. Furthermore, glycoinositol- phospholipid-modified CD8, when anchored to membraneε, and even CD8 anchored to fixed cellε, both maintain the inhibitory capacity of the native CD8 molecule. Hence, CD8-mediated inhibition is dependent upon the physiological status of the responding (target) cell, but is independent of the phyεiological εtatuε of the inhibitory cell. The latter point lays the groundwork for developing compositions comprised of membrane-binding CD8 derivatives linked to liposomes or other membranous therapeutic vehicles or of soluble CD8 derivatives.

One embodiment of a CD8 composition according to the present inven¬ tion comprises the complete extracellular region of CD8 [encompassing amino acids 1 (Ser) through 160 (Cys) of processed human CD8; for CD8 coding sequence, see Littman, D.R. , et al. , Cell 40:237-246, 1985]. An alternative CD8 composition is comprised of a functional domain within the extracellular region of CD8, εuch as one corresponding to the immunoglobulin V homologue region of CD8 [encompassing amino acids 1 (Ser) through 114 (Ala) of processed human CD8]. Protein engineering strategies using recombinant DNA tools for molecularly dissecting a protein εuch as CD8, to define functionally active subcomponents, are well known to those familiar with the art, and hence can be used to define additional functional CD8 peptide domains which retain the inhibitory ligand activity of the natural CD8 peptide. In addition to εuch CD8 peptide domain derivativeε generated through large block deletionε, numerouε other modificationε to the primary εtructure itεelf by deletion, addition, or alteration of the amino acidε incorporated into the sequence during translation can be made, creating various CD8 "muteinε," without deεtroying the inhibitory ligand activity of the CD8 peptide. Such substitutions or other alterations reεult in peptideε having an amino acid sequence substantially equivalent to that of CD8 and are encompassed within the scope of the present invention. Furthermore, while the examples offered herein are focused on the human CD8 molecule, CD8 molecules of other higher vertebrate specieε can be εimilarly engineered and employed, by virtue of their inhibitory ligand activity, for the modulation of immune and non-immune cells, and these also fall within the scope ot the present invention. Another embodiment of a CD8 peptide composition according to the present invention comprises a CD8:ligand conjugate, wherein CD8, or a functional peptide derivative thereof, is covalently linked to one or more secondary ligand molecules, the latter permitting the selective targeting of, and providing a costimulatory signal to, a specific subset of cells. The second ligand molecule of such a "bipartite CD8 ligand" can be peptidic or nonpeptidic in nature. In the case of peptide ligands, the CD8 and second ligand peptides can be linked in a linear or branched polypeptide chimera (vide infra). Additional ligands (third, etc.) can be similarly linked, and by utilizing such a "multipartite CD8 ligand," the effectiveness of the invention can be enhanced. Further¬ more, membrane-binding or soluble forms can be produced. Several examples of CD8:ligand conjugates will now be cited, which serve to illustrate, but in no way restrict, the types of such CD8-based conjugates that can be produced and used for cellular modulation. One example of a CD8:ligand conjugate is a CD8:MHC conjugate, wherein a CD8 peptide is covalently linked to a class I or class II MHC protein, or a functional peptide derivative thereof. Functional MHC peptide derivatives are comprised of those domains that are sufficient, and maintain the capacity in the synthetic peptide, for constituting a nominal antigen peptide (NAP) binding site. In the case of class I MHC, which is composed of a polymorphic, transmembrane α heavy chain and a noncovalently-associated, nonpolymσrphic, non-membrane-anchored β₂- microglobulin light chain, the o^ and o^ extracellular domains of the α heavy chain together constitute a NAP binding site (Bjorkman, P.J., et al. Nature 329:506-512, 1987). In the case of class II MHC, which is composed of noncovalently-associated, polymorphic, transmembrane α and β chains, the c^ domain of the α chain and the β₁ domain of the β chain are sufficient for constituting a NAP binding site (Brown, J.H., et al. Nature 332:845-850, 1988). NAPs can be associated, noncovalently or covalently, with the CD8:MHC conjugate to confer antigenic specificity to said conjugate, and permitε targeting of specific T cells.

A second example of a CD8:ligand conjugate is a CD8:unprocessed antigen conjugate, wherein a CD8 peptide is covalently linked to an unprocessed antigen, the latter constituting a ligand for immuno- globulinε on the surface of specific B cells. Examples of unprocessed antigens include allergenε, such as benzyl-penicilloyl, insulin, ovalbu- min, lactalbumin, grasε pollens, ragweed pollen, ragweed antigen E, tree pollens, bee venom, snake venom, and house dust mite, and self-antigens. Such conjugates permit targeting of specific B cells and are used to induce antigenic unresponsiveness and tolerance in humoral immune responses.

A third example of a CD8:ligand conjugate is a CD8:Fc conjugate, wherein a CD8 peptide is covalently linked to the Fc domain of an immunoglobulin molecule, or a functional, Fc receptor (FcR)-binding derivative thereof. Fc domains corresponding to any of the immuno¬ globulin isotypeε can be employed for thiε purpoεe. Such a conjugate permitε targeting of specific classeε of Fc-receptor bearing cells. Thiε, in turn, can εerve one of two purposes from a functional stand- For certain FcR-binding cellε, an inhibitory signal will be transduced by the CD8:Fc conjugate. Even in the absence of an inhibitory effect, the CD8:Fc conjugate will bind to the surface receptors, serving to coat the cell surface with CD8. This, in turn, serves to convert an FcR-positive antigen presenting cell into an inhibitory cell. A fourth example of a CD8:ligand conjugate is a CD8:Fv conjugate, wherein a CD8 peptide is covalently linked to a synthetic Fv (antigen- binding) domain of an immunoglobulin molecule, or an Fv-containing pep¬ tide. The Fv component confers specificity for specific cell surface- associated molecules bound by the Fv component, and thereby permits targeting of specific cellε.

A fifth example of a CD8:ligand conjugate iε a CD8:cytokine conjugate, wherein a CD8 peptide is covalently linked to a peptidic cytokine. A broad array of cytokines can be used for this purpoεe, including colony stimulating factors, interleukins and hormoneε. Such conjugates permit targeting of specific cytokine receptor-bearing cells. A sixth example of a CD8:ligand conjugate is a CD8:lectin conjugate, wherein a CD8 peptide is covalently linked to a lectin. A broad array of lectins can be uεed for this purpoεe, including conconavalin A and phytohemagglutinin. Such conjugateε permit targeting of specific normal and transformed cells bearing defined, lectin- eactive carbohydrate specificitieε on their surfaces.

A seventh example of a CD8:ligand conjugate is a CD8:anti-Id conju¬ gate, wherein a CD8 peptide is covalently linked to an anti-idiotypic (anti-Id) mimic of a second ligand, such as one of those described heretofore. Additionally, an anti-Id can be used as a mimic of CD8 itself in any of the CD8 compositionε deεcribed heretofore.

CD8 peptideε, compriεing either CD8 sequences only or CD8 sequenceε coupled to peptide or nonpeptidic ligands in CD8:ligand conjugates, can be soluble or membrane-binding. Coding sequences can be genetically engineered to create soluble forms by introducing a translational stop codon into the coding sequences of CD8 and peptide ligands, upstream of the hydrophobic transmembrane domains, using site-specific mutagenesis technologies. Coding sequences can be genetically engineered to create membrane-binding forms by linking, or retaining the linkage of, the coding sequences of CD8 and εecondary peptide ligandε to: 1) coding εequenceε for hydrophobic extenεion peptides of transmembrane proteins; or 2) coding sequenceε that direct glycoinositolphospholipid modifi¬ cation of peptides inεide cellε. A glycoinositolphospholipid-modified CD8 peptide represents a preferred embodiment of a membrane-binding CD8 peptide, according to the present invention, since it can be readily incorporated into biomembranes when exogenously added to them.

Linear polypeptide chimeras, in the formε of glycoinoεitol- phoεpholipid-modified protein intermediates and CD8:ligand conjugates, as discloεed in the preεent invention, can be readily produced by recombinant DNA technology. Chimeric transcriptional cassettes can be assembled using restriction endonuclease site overlap or the polymerase chain reaction (PCR)-based splice-by-overlap-extension (Horton, R. , et al.. Gene 77:61-68, 1989) methodologies, (i) To produce glycoinositol- phospholipid-modified peptides, the coding sequence for the peptide of interest is linked in-frame to the coding sequence for the 3' end of a protein that naturally undergoes glycoinoεitolphoεpholipid modification, such as decay accelerating factor (DAF). The chimeric protein produced in thiε way undergoeε glycoinoεitolphoεpholipid modification inεide the cell. This glycoinositolphospholipid-modification process was dis¬ covered by one of the inventors of the present invention (M.L.T.), and it was first applied to CD8 (Tykocinski, M., et al., Proc. Natl. Acad. Sci. U.S.A. 85:3555-3559, 1988); in parallel experiments, this proceεε has been independently applied to reporter peptides other than CD8 (Science 238:1280-1283, 1987). Diverse types of glycoinositolphospho¬ lipid membrane anchors, differing in biological characteristics such as phoεpholipase cleavability, are currently known, with the precise chemi¬ cal composition (e.g., number of fatty acid and carbohydrate residue unitε) dictated by the particular hoεt cell. Hence, the nature of the glycoinoεitolphoεpholipid moiety in the modified CD8 peptide can be determined through appropriate choice of the hoεt cell to be tranεfected with chimeric DNA sequence, (ii) To produce CD8:ligand conjugates, the DNA coding sequenceε for a CD8 peptide, a εuitable linker peptide, and the ligand peptide are tandemly linked in-frame. Choice of promoters, for the chimeric gene transcriptional cassette, vectors and host cells will dictate the nature of poεt-translational modifications introduced into the chimeric protein and the quantity of protein produced. For instance, baculovirus promoters and vectors can be used in insect host cells to produce large quantities of glycosylated CD8 compoεitionε.

Variouε recombinant DNA εequenceε have been aεεembled for generating glycoinoεitolphospholipid-modified and soluble CD8 peptides. Starting material for these DNA constructions are either PCR-cloned specific mRNAs from reverse tranεcribed poly(A+)RNA or obtained cDNA cloneε for human CD8 (for nucleotide εequence, see Cell 40:237-246, 1985; ATCC depoεit no. 59565), human DAF (for nucleotide sequence, see Proc. Natl. Acad. Sci. USA 84:2007-2011, 1987), human class I MHC α heavy chain of the A2 haplotype (for nucleotide sequence, see J. Immunol. 134:2727- 2733, 1985), human GM-CSF (Science 228:810, 1985; Proc. Natl. Acad. Sci. USA 82:4360, 1985; ATCC deposit nos. 39754, 57595 and 59171), human IgGl heavy chain γl (for nucleotide sequence, see Nucleic Acids Res. 10:4071- 4079, 1982), and human IgE heavy chain ε (for nucleotide sequence, see Cell 29:691-699, 1982). Examples of CD8 peptides include, but are not restricted to, the following: (i) Production of a glycoinositolphospholipid-modified CD8 peptide, encompasεing the complete extracellular domain of CD8 (through aεp 161), by a restriction endonuclease-based methodology. Specifically, the 3' end of DAF cDNA is cut at the Ava II site (nucleotide position 858), this site iε blunted by filling-in with Klenow fragment, and the CD8 coding segment cut at the EcoRV site (nucleotide position 609) is blunt-end ligated to the filled-in Ava II εite of DAF. Thiε createε a CD8:DAF chimera, which undergoeε glycoinoεitolphoεpholipid-modification inεide cellε (Tykocinεki, M.L., et al. Proc. Natl. Acad. Sci. USA 85:3555-3559, 1988). (ii) Production of a glycoinoεitolphoεpholipid- odified CD8 peptide, encompaεεing the immunoglobulin V-homologue domain of CD8 (through ala 114), by a εplice-by-overlap extenεion methodology. Specifically, the CD8 εequence (εpanning nucleotide poεitionε 31 through 470) iε PCR- a plified (denaturing 94°C, 2'; annealing 50°C, 2'; polymerizing 72°C, 2'; using Perkin Elmers-Cetus, Inc. thermal cycler and Gene-Amp kit) with the oligonucleotide primers a [5'-GGATCCAAGCTTCTCGAGAGCTTCGAGCCAAGCAGC- 3'] and b[5'-CJ^CTCTTGGTGGGACCC^^GGCAGGAAG-3' ] , and the DAF sequence (spanning nucleotide positions 859 through 2008; starting at val 258) is PCR-amplified with the oligonucleotide primers c[5'-CAGCGGTCCCACCA-

ACAGTTCAGAAACCT-3' ] and d[5'-GAGCTCGAG^ΛGC riGGCATCATTTATrT-3' ] . Primer a adds BamHI, Hind III, and Xhol sites to the 5'-end, and primer b adds Hind III, Xhol, and Sac I sites to the 3'-end. Primers b and c each bridge both CD8 and DAF sequence, and are complementary to each other at their 5' endε. Hence, the εeparate CD8 and DAF PCR products, when diluted (1:100), combined, denatured and reannealed, yield a subεet of chimeric CD8:DAF moleculeε, which are then PCR-amplified with the a and d primers (94°C, 2'/37°C, 2'/72°C, 2' for 10 cycles; 94°C, 2'/50°C, 2'/ 72°C, 2' for the next 20 cycles). The CD8:DAF chimera is gel-purified, digeεted with Hind III at its ends and ligated into the Hind III site of the Bluescript prokaryotic cloning vector (Stratagene, Inc., San Diego, CA) . An alternative version of a chimeric CD8:DAF gene, in which the coding sequences for the membrane-proximal 0-glycosylation region of DAF are omitted, is produced by subεtituting primers b and c for primers e[5'-CACTTCCTTTATTTGGCGCTα3CAGGAAGACC-3'] and f[5'-CAGCGCCAAATAAAGGAA- GTGGAACCACT-3' ] , respectively. The f and g primer pair PCR amplifies the DAF sequence spanning nucleotide positionε 1018 through 2008 (starting at pro 311).

(iii) Production of a soluble CD8 peptide, encompassing the V- homologue domain of CD8 (through ala 114), by a PCR-based site-directed mutagenesis methodology (Ho, S.N., et al. Gene 77:51-59, 1989). Spe¬ cifically, the CD8 sequence (spanning nucleotide positions 31 through 470) is PCR-amplified with the oligonucleotide primers a (as above) and

The g primer inserts a stop codon immediately downεtream of ala 114 and adds Sac I, Xho I and Hind III sites to the 3' end. The PCR-amplified DNA segment is digested with Hind III and ligated into the Bluescript cloning vector.

(iv) Production of a soluble CD8:MHC conjugate, encompassing the complete extracellular domains of both CD8 and the class I α heavy chain of the A2 haplotype, by a splice-by-overlap-extension methodology. Specifically, primers, with suitable complementary overlap εequences, are used to PCR-amplify and link in-frame the coding sequenceε for the α₁-c<₂-α₃ extracellular multidomain unit of the A2 claεε I α heavy chain (through trp 274), a linker peptide with minimal εecondary structure, and the extracellular domain of CD8 (through aεp 161). The linker peptide iε comprised of the repeating unit (GlyGlyGlyGlySer)₃ , and it is generated from complementary oligonucleotides produced on an oligonucleotide εyntheεizer (PCR-Mate, Applied Bioεyste ε, Inc.). A genetically engineered claεε I β₂-microglobulin can be secondarily associated with the class I α chain. Alternatively, an O^ -O , (through thr 182), instead of an o^-c^-α., MHC multidomain unit is incorporated into such a conjugate. Poεitioning of the c^-o^ MHC multidomain unit at the amino terminus of either of these linear polypeptide chimeras permits the component c^ and α. units to fold, as they do in their native state, to constitute an antigen-binding pocket.

(v) Production of a soluble CD8:GM-CSF conjugate, encompassing the complete extracellular region of CD8 (through asp 161) and complete GM-CSF (through glu 127), by a εplice-by-overlap-extenεion methodology. An analogouε approach to that used for the CD8:MHC conjugate is used, wherein the coding sequences for GM-CSF, a flexible linker peptide, and CDδ's extracellular region are linked. The capacity for binding to GM-CSF receptorε iε retained by thiε chimera.

(vi) Production of a soluble CD8:Fcγl conjugate, encompassing the complete extracellular domain of human CD8 (through asp 161) and the Fc region of the human IgGl heavy chain (γl), by a splice-by-overlap- extension methodology. This CD8:Fc conjugate differs from the CD8:MHC and CD8:GM-CSF conjugates, detailed as examples above, in two ways: 1) this CD8:ligand conjugate has the CD8 component positioned at the amino terminal end of the chimeric protein; and 2) the CD8 and ligand compo¬ nents of this CD8:ligand conjugate are connected to each other without an intervening linker peptide. Primers, with suitable complementary overlap sequences, are used to PCR-amplify and link in-frame the coding sequences for the complete extracellular domain of CD8 and the complete constant region of the human γl heavy chain, encompassing the C_H1^«C_H2- C_H3 multidomain unit starting at ala 114. Specifically, the CD8 sequence (spanning nucleotide poεitionε 31 through 611) iε PCR-amplified with the primers a and h[5'-TGGTGGAGGCATCACAGGCGAAGTCCAG-3' ] , and the γl sequence with primers i[5'-CIGTGATGCCTCCACCAAGGGCCCATCGGT-3' ] and j[5'-GTACGTGCCAAGCATCCTCGTGCGACCG-3']. This CD8:Fc conjugate can be iεolated by εtaphylococcuε protein A-εepharoεe chromatography, by virtue of the retained capacity of the Fc domain of the diεulfide-linked polypeptide chimera dimer to bind to protein A. In a similar fashion, a soluble CD8:Fcε conjugate is asεembled, incorporating the C_H1^«C_H2^«C_H3- C_H4 multidomain unit of human IgE. Specifically, the CD8 segment (spanning nucleotide positions 31 through 611; ending at asp 161) is PCR-amplified with primers a and k[5'-GTGTGGAGGCATCACAGGCGAAGTCCAG-3'] and ε(spanning nucleotide positionε 98 through 1847; εtarting with ala 114) is PCR-amplified with primers 1[5'-CTGTGATGCCTCCACACAGAGCCCATCC- GTCTTC-3' ] and m[5'-GTCΑTTGCAACAGTGGACAGAAGGTCT-3' ] .

Branched polypeptide chimeras, in the form of CD8:ligand conjugates, can be readily produced by template-assembled synthetic peptide (TASP) technology (Mutter, M., Trends Biochem. Sci. 13:260-265, 1988). By this procesε, the peptide unitε are synthesized separately and covalently coupled to a multifunctional carrier, εuch aε a core peptide, uεing chemical coupling reagents. For example, a cyclic decapeptide analogue of gramicidin S, in which two antiparallel β-sheet segmentε (lys-ala-lys) are linked by two β-turnε, can be used as a core peptide. Segment condensation strategies can be used to attach CD8 and secondary ligand peptides to the ε-amino groups of the 4 lysine side chains. Alternatively, CD8 and ligand components can be covalently linked directly to each other in branched structures using chemical cross- linking reagents. By this methodology, for example, CD8 and Fc dimerε can be directly linked. Branched, as opposed to linear, polypeptide chimeras are particularly well-suited for providing for multivalent CD8:ligand conjugates (vide infra), with varying CD8 to ligand ratios.

To facilitate the biochemical isolation of the various CD8 composi- tionε disclosed heretofore, the primary amino acid sequence of the CD8 peptide, or in the special case of CD8:ligand conjugates, the primary amino acid sequence of either the CD8 or ligand peptides, can be altered through genetic engineering strategies. A particularly useful altera¬ tion is the inεertion of two or more neighboring hiεtidine residueε. This insertion can be in the amino or carboxy terminus of the peptide. Additionally, for CD8:ligand linear polypeptide chimeras, the hiεtidineε can also be inserted into the linker peptide, and for CD8:ligand branched polypeptide chimeras, the histidineε can also be inserted into the core peptide. Histidine reεidue inεertionε can be readily accom¬ plished by the splice-by-overlap extension methodology, by incorporating histidine-encoding CAT and CAC triplet codons into the PCR primers at suitable locations in the coding sequence. Hiεtidine-modified proteins can be efficiently and quantitatively isolated by nickel-sepharose chromatography. The hiεtidine-nickel interaction iε based upon protonation, and hence this interaction can be reversed, for purposes of peptide elution, through a simple pH shift. Another primary amino acid εequence alteration of a CD8 peptide designed to facilitate its biochem¬ ical isolation from transformed or transfected host cells is the addi¬ tion of a hydrophilic extension peptide, usually to the carboxy-terminus of said peptide. Antibodies with specificities directed aginst a given extenεion peptide can be uεed as an immunoaffinity reagent to effi¬ ciently purify the CD8 peptide from complex peptide mixtures. Suitable hydrophilic extension peptides assume minimal secondary structure, project outward from the core CD8 peptide and are readily cleaved from the CD8 peptide by mild proteolytic digestion following the antibody- based purification procedure. Other primary sequence modifications, such as the insertion of reactive amino acids for εpecific chemical coupling reagentε, can alεo be performed. Alternatively, more conventional, and conεiderably leεs efficient biochemical isolation strategieε can be employed, including those based upon immunoaffinity (e.g., anti-CD8 primary antibodies).

The variouε membrane-binding and εoluble CD8 and CD8:ligand peptideε deεcribed herein can be readily produced in large quantitieε using current recombinant DNA technologieε. Techniqueε for manipulating DNA εequenceε and introducing them into cellε, and combinations of chromosomally-integrating or extrachromosomally-replicating DNA expresεion vehicleε and prokaryotic or eukaryotic hoεt cells suitable for the quantitative production of recombinant peptides are now well established in the art (for examples, see U.S. Pat. Nos. 4,677,063; 4,677,195; 4,703,008; 4,727,138; 4,833,127; 4,847,201; 4,853,330) and can be readily applied to the large-scale manufacture of recombinant CD8 peptides for pharmaceutical purpuses.

Another embodiment of a CD8 composition according to the present invention comprises biomembranes coated with CD8 (and a second ligand) or CD8:ligand peptides. These biomembranes can be in the form of, but are not restricted to, cells, lipoεomes, planar membranes or pseudocytes (Goldstein, S.A. , et al. J. Immunol. 137:3383-3392, 1986). Cells that naturally bear CD8, such aε CD8-poεitive T lymphocyteε, or that are coated and/or genetically engineered to bear CD8 can be alternatively utilized. A cellular form that is particularly well-suited, as a therapeutic agent, for modulating cells in the blood compartment are autologous, or heterologouε blood group-matched, erythrocyteε coated with CD8 peptideε. The applicability of lipoεomes for pharmaceutical purpoεeε haε been documented extenεively in U.S. patent filings. CD8- coated liposomes, as disclosed in the present invention, can additional¬ ly be internally loaded with organic and inorganic constituents, such as cytokines and toxins, to be targeted to specific cells. A glycoinositol- phσspholipid-modified CD8 peptide is a preferred membrane-binding CD8 composition according to the present invention, to be used for coating biomembranes, since said peptide, so modified, can be readily incor¬ porated into biomembranes in the presence of low, non-lytic concentra¬ tions of detergents. Both free cells and cells embedded in a tissue matrix can be coated with glycoinositolphospholipid- odified CD8 peptides. Another membrane-binding CD8 composition is a CD8:Fc conjugate which permitε the efficient coating of Fc receptor-bearing cellε. Another coating proceεε entailε the uεe of cross-linking chemical reagents to bind a CD8 peptide to biomembranes. Various processes for covalently coupling peptides to liposomes have been disclosed (see, for example, U.S. Pat. Nos. 4,565,696 and 4,762,915). Yet another means of producing cells coated with a CD8 peptide is through the use of gene transfection technology. By any of these coating processes, multiple additional molecules can be added to the biomembrane to enhance the biological potency of the CD8 peptide. The various acellular therapeutic biomembrane preparations described heretofore can be stored in a dehydrated form, and packaged into kits, for pharmaceutical use.

Another embodiment of a CD8 composition according to the present invention comprises short CD8 peptides that do not retain the inhibitory ligand activity of natural CD8 peptides, but can competitively inhibit the binding of natural CD8 to its natural receptor. Such short CD8 peptideε can be uεed aε nonspecific immunopotentiators in blocking natural CD8-dependent immunoregulation. General methods for designing short peptide inhibitors for a specific peptide such as CD8, are well known to those skilled in the art.

One embodiment of a CD8-mediated therapeutic process according to the present invention comprises the use of a CD8 peptide, as disclosed in the present invention, to inhibit specific cells in vivo or in vitro. This process is of particular applicability for purposes of specific immunotolerization and deriveε from our novel finding of CDδ'ε pivotal role in natural immunoregulation. The CD8-mediated inhibitory effect is contingent upon the εimultaneouε copreεentation of a molecular εignal that normally, in the absence of CD8, contributes to cellular activation. This second signal can be provided by a second molecule noncovalently aεεociated with CD8, by virtue of its presence on the same biomembrane with CD8, or covalently associated with CD8 in an artificial CD8:ligand conjugate. The nature of the second, noncovalently or covalently, associated ligand dictates the nature of the target cell to be inhibited. Specific T cellε can be inhibited by CD8 in aεsociation with allogeneic MHC or an MHC:NAP complex. Other specific target cells can be selectively inhibited using other CD8:ligand combinations as cited (vide supra). The treatment of target cellε to be inhibited can either be in vitro, prior to infuεion of the cell population into the subject, or in vivo, wherein the CDδ composition is administered directly to the subject.

As an example of a CDδ-mediated immunomodulatory therapeutic process, the sequence of stepε that can be executed for inducing tolerance in a proεpective tranεplant recipient for the allogeneic MHC polypeptides of the transplant donor, in order to prevent immunological rejection of the graft following tranεplantation, are as follows:

(i) Chimeric gene constructs are assembled, within the Bluescript cloning vector, for producing glycoinositolphospholipid-modified peptide derivatives of human CDδ, specific donor allo-class I MHC α heavy chains and εpecific donor allo-class II MHC α and β chains. In each case, the coding sequence for the extracellular domain of the respective poly¬ peptide is linked in-frame to the 3'-end DAF coding sequence, the latter encompassing the signalε that direct the glycoinoεitolphoεpholipid modification proceεs inside of cells. In addition, the complete coding sequence for the nonpolymorphic claεε I MHC β₂-microglobulin light chain iε subcloned into the Bluescript cloning vector. The PCR-based splice- by-overlap-extension methodology is used, as detailed above, to assemble these genetic constructions, and primers designed to insert 4 neighbor¬ ing histidine residues at the peptide:DAF junction and 3' end of β₂-microglobulin are employed.

(ii) Theεe coding sequences are mobilized by restriction endo- nucleaεe digeεtion from the Bluescript cloning vector, using flanking restriction endonuclease εiteε in the multiple cloning εite of this vector, and each is inserted into the baculovirus expreεsion vector pVLl392 (obtained from Dr. Max Summers, Texas A&M University) which iε suited for gene casεetteε containing their own tranεlation initiation signals.

(iii) 2 μg of each expression construct is cotranεfected into Spo- doptera frugiperda (Sf)9 cells in combination with 1 μg Autographa cali- fornica nuclear polyhedrosis virus DNA, in order to produce recombinant viruses for protein expression. By the fourth day post-transfection, up to 50% of the cells have viral occlusionε viεible in the nucleuε and the viruε titer is approximately 10⁷ pfu/ml; recombinant viruses account for up to 5% of the viral plaques. Purification of viral recombinants is achieved by three rounds of plaque purification.

(iv) Each group of Sf9 cells, infected with plaque-purified recombi¬ nant virus, is harvested, lysed in 1% NP-40 in phosphate-buffered saline containing 50 μg/ml of the synthetic elastase inhibitor Suc(OMe)-Ala- Ala-Pro-Val-MCA (Peninsula Laboratories, Inc., Belmont, CA) and 1 mM phenylmethylsulfonylfluoride (Sigma Chemical Co., St. Louis, MO). Each detergent lysate is pasεed over a 5 ml nickel-εepharose column, and in each case, a polypeptide mixture, highly enriched for the respective over-expressed peptide is eluted from the nickel-sepharose matrix by a pH shift, according to the standard protocol, and dialyzed against neutral buffer. Peptides so produced can be prepared in advance and packaged into kits.

(v) Unilamellar liposomes coated with glycoinositolphospholipid- modified CDδ, claεε Iα, class Ilα, clasε Ilβ and unmodified claεs I β₂-microglobulin are prepared by a detergent dialysis method (see, for example, Milsmann, M., et al. Biochim. Biophyε. Acta 512:147, 197δ), wherein a mixture is prepared containing egg lecithin, cholesterol, diacetyl phosphate, and glycoinositolphospholipid-modified peptides in a molecular ratio of 2:1.5:0.2:0.01. The mixture is dissolved in a chloroforπumethanol solution (2:1) containing 1% sodium cholate, and this lipid-detergent mixture is subεequently rotary evaporated in a round-bottomed flaεk, depositing a thin dry film. Liposomes form spontaneously when the lipid film is redissolved in phosphate-buffered saline (0.1 M, pH 7.3). Detergent and excess reagents are removed by dialysis against several changes of 0.05 M Tris, pH 7.6, and the final concentration of these peptide-coated liposomes is adjuεted in Tris buffer εo that phoεpholipid content iε 12 mol/L. A broad array of U.S. patent filings describe alternative liposomal compoεitions, incorpor¬ ating various synthetic lecithins, modified cholesterolε and negative- charged molecules other than diacetyl phosphate, and methods for preparing said liposomal compositions, and these can be readily adapted for preparing CDδ-coated liposomes. An alternative to adding the glycoinositolphospholipid-modified peptides to the original mixture of liposomal constituents is to secondarily incorporate said peptides into formed liposomes in the presence of .003% NP-40. These peptide-coated liposomeε can be stored in a dehydrated state and packaged into kits (see, for example, U.S. Pat. Nos. 4,746,516 and 4,766,046) or used immediately for immunomodulation. (vi) A subject who is to undergo a transplant is assessed for allo- reactivity to donor allo-MHC by isolating peripheral blood mononuclear cellε from the proεpective tranεplant recipient'ε blood, and setting up a mixed lymphocyte reaction (MLR) with these recipient PBMC as respon¬ ders and irradiated (5000 R) donor PBMC as stimulatorε. If a εignifi- cant proliferative response is noted, a pharmaceutical composition com¬ prising the peptide-coated liposomeε, corresponding to donor allo-MHC, are infuεed intravenouεly 6-δ weekε prior to the planned transplantation procedure.

(vii) At 3-4 weeks prior to the transplantation date, the in vitro MLR asεay iε repeated, and if a residual proliferative response between recipient responders and donor stimulators persists, the coated liposome preparation is reinfused.

(viii) To further enhance engraftment, cells of the graft are coated with CD8 prior to transplantation (vide infra). (ix) The MLR aεεay iε repeated at 6 month intervalε post- transplantation, and booster doses of the CD8 composition are adminis¬ tered systemically aε required.

Of note with respect to this particular example of an iπrmunomodulatory process for prospective transplant recipients are the following: 1) Polymerase chain reaction technology now permits the expeditious cloning of the array of allo-MHCs that are present in the human population, and this technology further provides for the rapid assembly of MHCOAF gene chimeras. 2) Nominal antigen peptideε (NAPs), representing processed peptides of MHC and other polypeptides, can be added to liposomeε or other therapeutic biomembrane preparationε bearing CDδ and self-MHC, for immunomodulation to both allogeneic and other antigens. This approach permits the treatment of the broad range of autoimmune, allergic and other human diseaseε where there are unwanted, εpecific T cell immunoreactivitieε. 3) Instead of using liposomes (or other therapeutic biomembrane preparationε) coated with separate CDδ and allo-MHC peptideε, liposomeε coated with CDδ:MHC (covalent) conjugates or soluble CDδ:MHC (covalent) conjugates can be administered to the prospective transplant recipient. As another example of a CDδ-mediated immunomodulatory therapeutic procesε, the sequence of steps that can be executed for inducing immunotoleranee to self antigens, in preventing or treating autoimmune diseases, are as follows: (i) Autologous cellε that are capable of antigen processing and presentation, such as monocytes/macrophages, are obtained from a εubject.

(ii) Theεe antigen preεenting cells (APCs) are coated with CDδ pep¬ tideε in vitro. Thiε can be readily acco pliεhed using CDδ pharmaceuti- cal compositions comprising glycoinositolphospholipid-modified CDδ peptideε or suitable CDδ:Fc conjugates, the latter binding to the Fc receptors of the APCs.

(iii) Purified peptides or complex peptide mixtures, comprising the targets of autoimmune reactivity, are added to the CDδ-coated APCs, and following a procesεing interval, the cells are reinfused into the εubject. This treatment process is repeated at set intervals.

This therapeutic process for autoimmunity obviates the need for knowing in advance precisely which peptides are the critical targets of autoimmune attack, as even crude cellular extracts, comprising unprocessed antigen, from known target tissues can be added to the APCs. Alternatively, where a precise peptide target is in fact known for a specific disease (e.g., acetylcholine receptor in myasthenia gravis; thyroglobulin in Hashimoto's thyroiditis) , purified peptide, comprising unprocesεed antigen, can be added to the APCε. Furthermore, where the functionally relevant processed peptides have been defined, these peptides can be synthesized and added to any CDβ-positive cell capable of antigenic presentation, obviating a requirement for antigenic processing.

The effective subunit valency of the CDδ and ligand components in soluble CDδ:ligand conjugates dictates the potency of the biological effect exerted upon target cells. Multivalent conjugates, wherein more than one CDδ peptide subunit and/or more than one ligand subunit are covalently linked in each conjugate molecule, are functional equivalents of membrane-linked multimolecular CD8:ligand combinations. In contrast, univalent conjugates, wherein one CD8 peptide subunit and one ligand subunit are covalently linked in each conjugate molecule, can, in certain instances, demonstrate lower efficacy. In vitro cellular assays, such as mixed lymphocyte cultureε and colony forming assays, that can be used to predict the in vivo effect of a given CDδ:ligand conjugate, with a defined subunit valency, are well known to those familiar with the art. Furthermore, in vivo asεeεεment of the activity of a given CDδ composition can be performed in a suitable experimental animal. For instance, human CDδ compositionε can be studied in severe combined immunodeficiency disease (SCID) mice reconstituted intraperitoneally with mature human immune cells.

Another embodiment of a CDδ- ediated therapeutic process according to the present invention compriseε the uεe of CDδ:Fc conjugateε for generalized, nonspecific immunoεuppreεsion. These conjugates, in their soluble forms, bind to Fc receptors (FcR) on various FcR-bearing cells in an immunoglobulin isotype-specific fashion. Antigen presenting cells, one set of cells that bear FcRs on their εurfaceε, can in thiε way be coated with CDδ, and in turn, the antigen-specific activation function of these cells can thereby be converted to an antigen-specific inhibition function. This, in effect, provides a way to block all antigen presenting cell-dependent immune responεeε in a general fashion. In clinical situationε where there is broadly increased polyspecific reactivities, e.g., syεtemic lupuε erythematoεuε, the adminiεtration of CDδ:Fc conjugateε permit polyclonal εuppreεεion. Another therapeutic application for CD8:Fc conjugates is the inhi¬ bition of specific FcR-bearing cells. This is of particular relevance for the therapy of allergic disorders, such as atopic (igE-mediated) asthma, where Fcε-mediated degranulation of FcεR-positive mast cells and basophils, leading to the release of mediators such as histamine, is a primary pathogenetic mechanism. A CD8:Fcε conjugate can be used to eliminate the untoward functional reactivities of these FcεR-positive cellε and FcεR-positive regulatory T cells that control IgE production by B cells. The Fcε sequence can be derived from either soluble of membrane ε heavy chain, and differences in the carboxy termini of these Fcε derivatives can influence regulatory T cell-based molecular interac¬ tions. For example, a CDδ-Fcε conjugate, or a therapeutic biomembrane preparation bearing CDδ and Fcε peptide units, is administered paren- terally to an allergic subject at 6 month intevalε. Allergy teεting iε performed yearly to monitor the therapeutic response. For subjectε with upper airway manifeεtationε of their allergic disease, intranaεal and inhalant drug formulations are particularly efficacious.

The use of CDδ:Fcε conjugates for inactivating FcεR-bearing cellε in allergic subjects represents a specialized application of the more general principle that CDδ-mediated inhibition can be applied in a pharmaceutical context for inhibiting a broad array of cell types. For example, a CD8: monocyte/macrophage-colony stimulating factor (M-CSF) conjugate can be uεed to inhibit M-CSFR-bearing cells that can normally be activated by M-CSF. This provides a therapeutic approach for dealing with clinical conditions in which there is excessive production of normal or transformed monocytes. Similarly, CD8:GM-CSF can be used to inhibit granulocyte-macrophage precursors. The nature of the target cells and the potential clinical applications for the various CDδ:ligand conjugates disclosed in the present invention will be apparent to those familiar with the art.

Yet another embodiment of a CDδ-mediated therapeutic process according to the present invention compriseε the uεe of CDδ peptides to promote engraftment of cells, tissues and organs, such aε kidney, heart, skin, and bone marrow. According to a preferred embodiment of this process, cells of a graft are coated with a membrane-binding CDδ pep¬ tide, and the graft, comprising CD8-coated cells, is then transplanted into the recipient. Glycoinositolphospholipid-modified CDβ peptides are membrane-binding CDδ compositions well-suited for this purpose, since, peptides so modified spontaneouεly incorporate into cellular membraneε in the presence of low, non-lytic concentrations of detergents (e.g., 0.003% NP-40; J. Exp. Med. 160:1556-1576, 1964). Coexpression of CDδ and allo-MHC on the graft cells serveε to inhibit alloreactive T cells, and thereby prolong graft survival through suppresεion of the rejection process. This process is applicable to a broad array of graft types. In the case of a vascularized solid tissue graft, the organ can be per¬ fused with a membrane-binding CDδ composition in order to coat the endo- thelial cells of the graft. Exogenouεly introduced CDδ, in association with endogenously expressed allo-MHC, on graft endothelial cells serves to inhibit allospecific host immune cells entering the tiεεue or organ and to mitigate acute graft rejection proceεεes directed against the endothelial lining. In the case of bone marrow and other grafts comprised of disperεed cellε, CDδ-coating of the cellε to be engrafted can be accomplished by combining the cells and a membrane-binding CD8 composition together as a suspension in a tissue culture flask. Not only are the CDδ-coated cells themselves protected from immunological rejection, but the transplantation of such CDδ-coated graft cells into a given body compartment further serves to convert said compartment into an im unologically privileged site for all cells with a shared allogeneic phenotype. This is of particular utility when long-lived graft cells are used. For example, allogeneic human bone marrow stromal cells can be coated with CDδ in vitro and transplanted into the host to convert the host's bone marrow into an immunologically privileged site for other cells with a shared allogeneic phenotype that can be engrafted at later times.

The clinical εetting of renal tranεplantation εerveε to exemplify a CDδ-coating proceεε for pretreating a εolid organ graft prior to trans¬ plantation, in order to block immunological rejection of the graft following transplantation, and the sequence of steps that can be executed in this case are:

(i) The kidney of a renal transplant donor is perfused, at the time of surgery and prior to itε resection, with 1 ml of a solution containing a glycoinoεitolphoεpholipid-modified CDδ peptide compoεition (vide εupra) via a bolus injection into the renal artery supplying that kidney, or alternatively, via a bolus infusion into said renal artery by means of renal arterial catheterization prior to surgery. The infused solution comprises the membrane-binding CDδ peptide in a .003% NP-40-containing normal saline diluent.

(ii) The kidney, once resected, iε kept at 4°C in a perfuεate sup- plemented with the membrane-binding CDδ peptide in .003% NP-40 until tranεplantation into the recipient.

The clinical εetting of bone marrow tranεplantation εerveε to exemplify a CD8-coating process for pretreating graft cells that are in a dispersed state prior to transplantation, in order to block immuno- logical rejection of the graft cells following transplantation, and the sequence of steps that can be executed in this case are:

(i) Bone marrow (approximately 15 cc/kg body weight for an adult) is aεpirated from a donor by methodε well known in the art (εee, for example, U.S. Pat. Noε. 4,481,946 and 4,486,186), and is immediately placed into cold TC-199 medium (Gibco, Inc.) supplemented with heparin (30,000 U/100 ml).

(ii) The bone marrow suεpenεion iε centrifuged in a Sorvall RC-3 at 3000 rp , 20', at ambient temperature. The plaεma supernatant is sepa¬ rated, and stored for later use. The marrow is transferred to 15 ml sterile polypropylene tubes, and these are centrifuged at 1500 g, 10', at 4°C.

(iii) The marrow buffy coat is recovered and transferred into a 2000 ml transfer pack for peptide-coating. The nucleated marrow cells are adjusted to a final concentration of 2 x 10⁷ cellε/ml, and hematocrit to <10% with TC-199 medium.

(iv) NP-40 iε added to the bone marrow εuspenεion to a final concentration of .003%, and a glycoinoεitolphospholipid-modified CD8 peptide composition in .003% NP-40 is added immediately thereafter. The mixture is incubated for 30' at ambient temperature, and the transfer pack is gently agitated every 5'.

(v) The bone marrow cells are transferred into cold satellite bags, and washed free of detergent and unbound CD8 peptide by serial centri- fugation (RC-3, 2200 g, 4°C, 10' each spin). The marrow cells are diluted with cold, irradiated autologous plasma to 8 x 10 nucleated cells/ml.

(vi) A 2 ml sample is taken for in vitro asεayε, and proceεεed by diluting 1:3 with cold TC-199, layering over 3 ml Ficoll-Hypaque (Pharmacia, Inc.), and centrifuging (500 g, 30', ambient temperature). The mononuclear cell layer is thrice washed and assessed for colony formation capacity in methyl cellulose.

(vii) The remaining CDδ-coated cells are mixed with cold freezing solution [60 ml TC-199 + 20 ml DMSO (Cryoserv Research Industries Corp.) + 20 ml irradiated, autologous plasma] at a 1:1 cell ratio.The cells are then incrementally frozen using computerized cryotechnological equipment (e.g., U.S. Pat Noε. 4,107,937 and 4,117,661) and stored in liquid nitrogen until infusion into the recipient.

The CDδ coating process is applicable to isografts, homografts, heterografts and xenografts. CDδ-coated cells, tissues and organs provide for "universal" donor material, permitting the circumvention of the limiting requirement imposed by currently available transplantation technologies for histocompatible cells, tissues and organs. For example, CDδ-coated epidermal cells can be used in a universal way for skin transplantation. The CDδ coating procesε can be applied not only to native, unmodified cells, but also to genetically engineered, or otherwise engineered, cells. Thiε permits the suεtained delivery of a defined gene product, to a εubject in need of εaid product, by uεing a CDδ-coated cell aε a cellular vehicle that can evade the host'ε immunological rejection mechaniεmε. For example, a tranεcriptional cassette, comprising the insulin gene driven by a suitable regulatory promoter element, can be transfected into human bone marrow stromal cells, and theεe engineered cellε can be coated with CD8 and tranεplanted into a diabetic εubject, in order to correct εuch a εubject'ε insulin deficiency. In the particular case of xenografts, the CD8 coating process offers the possibility of generating animal chimeras for experimental purposes. For example, a mouse can be reconstituted with murine CDδ-coated human hematopoietic progenitor cells. This bypasεeε the limitation of methodologieε currently employed for generating mouεe-human chimeraε, εuch as the reconstitution of a SCID mouse with human hematopoietic progenitor cellε, which require the use of an immunodeficient, and consequently hard to maintain, mouse as a host for the human cells. As described above, in addition to coating the graft cellε with CDδ, engraftment can be enhanced by pretreating the graft recipient with therapeutic biomembrane preparationε bearing CD8 and allo-MHC or with εoluble CD8:MHC conjugateε prior to tranεplantation, in order to induce specific immunotolerance to the allo-MHC of the transplanted cells, tissues or organs. Biomembrane compositionε that can be uεed for thiε purpoεe compriεe native or engineered cellε, lipoεomeε, planar membraneε, or pεeudocyteε. CD8:MHC conjugateε compriεing both claεε I and claεε II MHC componentε can be coadministered.

Still another embodiment of a CDδ-mediated therapeutic process according to the present invention compriεes the use of CD8 peptideε to prevent graft verεus-host diεeaεe when bone marrow iε tranεplanted to a non-identical recipient. A therapeutic biomembrane preparation, bearing both CD8 and hoεt MHC peptideε or a CD8:MHC conjugate is added to donor bone marrow cells in vitro, and following variable incubation periods, the cells are infused into the transplant recipient. This form of treatment eliminates alloreactive immune cells amidst the donor bone marrow cells, and mitigates the requirement for T-cell depleting the bone marrow.

In the clinical εituation of bone marrow tranεplantation, the variouε CD8-dependent inhibitory processes described heretofore can be combined in a multifacted way to inhibit both host-versus-graft and graft-versus-host responses. Aε an example, a εequence of steps that can be executed in this setting are:

(i) A CD8 peptide composition, comprising CDδ and donor allo-MHC, is adminiεtered to the tranεplant recipient 6-δ weekε prior to tranεplant¬ ation, with a booster dose at 3-4 weeks, if required, in order to suppress alloreactive cells of the recipient.

(ii) Bone marrow is aεpirated from the donor, NP-40 is added to the suspension to a final concentration of .003%, and a CD8 peptide composi- tion, compriεing CDδ and recipient allo-MHC, iε added to the bone marrow cellε, incubated for 4 h at 37°C, in order to inhibit alloreactive cells of bone marrow cell population.

(iii) Bone marrow cells are coated with a CDδ peptide composition, compriεing a membrane-binding CD8 peptide, and the cells are either stored in cryopreservative in liquid nitrogen until uεe or immediately infuεed into the tranεplant recipient.

The compoεitionε active in the novel methods of treatment of this invention can be administered in a wide variety of therapeutic dosage forms in conventional vehicles. A variety of effective formulations for peptide pharmaceuticals, as well aε doεing schedules for immunomodulatory agents, are known to those familiar with the art and can be applied to the CD8 peptides disclosed heretofore. Non-immunogenic carriers, such as carboxymethyl cellulose (U.S. Pat. No. 4,415,552), are particularly well suited for soluble CD8 compositionε. Therapeutic cellular preparationε for CDδ-baεed therapy are infuεed intravenouεly into the subject. Therapeutic liposome and other planar membrane preparations for CD8-based therapy can be administered parenterally or orally. Modulation of target cells is accomplished by administering to a subject, or treating cells of a subject in vitro, with a dose, or series of doses which will achieve the desired modulatory effect. The efficacy of cellular modulation, such as the degree of CD8-mediated immunomodulation, can be easily monitored using conventional in vivo and in vitro immunological testing methods, and booster doses can be administered as needed.

The industrial applicability of the variouε CD8-based pharmaceuti¬ cals of the present invention, particularly in the field of immune- therapeutics will be apparent to those skilled in the art from the description as set forth above and the appended claims. It is understood that various other modificationε will be apparent to and can readily be made by thoεe εkilled in the art without departing from the scope and spirit of this invention. Accordingly, it is not intended that the scope of the claims appended hereto be limited to the deεcription as set forth above, but rather that the claimε be conεtrued aε encompaεsing all the featureε of patentable novelty, enεuing from the disclosure of CDδ's inhibitory ligand activity, which would be treated as equivalents thereof by those skilled in the art to which this invention pertains.

Claims

1. A pharmaceutical composition comprising a CD8 peptide having cellular inhibitory activity.

2. The composition of claim 1 wherein said CDδ peptide comprises the complete extracellular domain of CD8, encompassing amino acid positionε 1 (Ser) through 161 (Aεp) of the natural, processed human CD8 peptide.

3. The composition of claim 1 wherein said CD8 peptide compriεeε a part of the extracellular domain of CD8, encompassing amino acid positionε 1 (Ser) through 114 (Ala) of the natural, proceεεed human CD8 peptide.

4. The composition of claim 1 wherein said CD8 peptide is membrane- binding.

5. The composition of claim 4 wherein said membrane-binding CD8 peptide compriεes a glycoinoεitolphoεpholipid moiety for membrane anchorage.

6. The compoεition of claim 1 wherein said CD8 peptide is soluble.

7. The composition of claim 1 wherein said CD8 peptide comprises two or more histidine residues, permitting its isolation by nickel-sepharoεe chromatography.

8. The compoεition of claim 1 wherein εaid CD8 peptide compriεes a hydrophilic extension peptide, permitting itε iεolation by immunoaffinity-baεed procedureε.

9. The compoεition of claim 1 wherein εaid CD8 peptide iε a CD8:ligand conjugate, comprising one or more εecondary peptide ligandε, in a linear or branched polypeptide chimera, or one or more εecondary nonpeptide ligandε.

10. The composition of claim 9 wherein the ligand component of said CDδ:ligand conjugate compriεeε a major hiεtocompatibility complex (MHC) peptide, or a functional peptide derivative thereof.

11. The composition of claim 10 wherein the MHC component of said CDδ:MHC conjugate comprises a class I MHC peptide.

12. The composition of claim 10 wherein the MHC component of said CD8:MHC conjugate comprises a class II MHC peptide.

13. The composition of claim 10 wherein said CD8:MHC conjugate is physically aεεociated with a nominal antigen peptide correεponding to a part of an unprocessed peptide antigen.

14. The composition of claim 9 wherein the ligand component of said CDδ:ligand conjugate comprises an unprocessed antigen.

15. The composition of claim 9 wherein the ligand component of said CDδ:ligand conjugate compriseε an immunoglobulin Fc domain, or a functional peptide derivative thereof.

16. The composition of claim 15 wherein the Fc component of said CD8:Fc conjugate comprises the Fc domain of IgGl heavy chain, or a functional peptide derivative thereof.

17. The composition of claim 15 wherein the Fc component of said CD8:Fc conjugate comprises the Fc domain of igE heavy chain, or a functional peptide derivative thereof.

18. The composition of claim 9 wherein the ligand component of said CDδ:ligand conjugate compriseε an immunoglobulin Fv domain, or a functional peptide derivative thereof.

19. The compoεition of claim 9 wherein the ligand component of said CD8:ligand conjugate compriseε a cytokine.

20. The compoεition of claim 9 wherein the ligand component of said CDδ:ligand conjugate compriseε a lectin.

21. The composition of claim 9 wherein the CD8 or ligand component of said CDδ:ligand conjugate comprises an anti-idiotypic mimic.

22. A DNA εequence comprising the coding sequence for a CDδ peptide, aε deεcribed in claim 1.

23. An expression syεtem compriεing the DNA sequence of claim 22 operably linked to suitable control sequences which are capable of effecting the expression of said coding sequence in transformed or transfected host cells.

24. A prokaryotic or eukaryotic host cell transformed or transfected with a DNA sequence according to claim 23 in a manner allowing the host cell to expresε said CDδ peptide.

25. A method for producing a CDδ peptide, as described in claim 1, which comprises culturing the cells of claim 24 under conditions effective for the production of said CD8 peptide.

26. A method for producing a glycoinositolphospholipid-modified CD8 peptide, as described in claim 5, comprising the stepε of: (i) aεεembling a chimeric DNA εequence in which a DNA εequence, encoding a peptide having an amino acid εequence εufficiently duplicative of that of natural CDδ to allow poεsesεion of the biological property of cellular inhibition, iε linked in-frame to the coding εequence for the 3'-end of a peptide that undergoes glycoinositolphospholipid modification in its natural state; (ii) inserting thiε chimeric DNA εequence into an expression system comprised of said DNA sequence operably linked to suitable control εequenceε; (iii) transforming or transfecting this assembled DNA sequence into a host cell; (iv) culturing the cellε under conditionε effective for the production of said peptide, and (v) isolating the glycoinositolphospholipid- modified CDδ peptide from these cells.

27. A pharmaceutical composition comprising a biomembrane bearing natural CDδ or a membrane-binding derivative of CDδ, as described in claim 1, having cellular inhibitory activity.

28. The compoεition of claim 27 wherein εaid biomembrane compriεeε a cell, or a cellular derivative thereof.

29. The compoεition of claim 28 wherein said cell compriseε a cell capable of processing and/or presenting antigen.

30. The composition of claim 27 wherein said biomembrane comprises a liposome.

31. A composition comprising a peptide that competitively inhibits CDδ's inhibitory ligand activity, thereby acting as an immunopotentiator.

32. A therapeutic method for specific immunomodulation comprising administering an effective amount of a CD8 peptide, aε described in claim 1, or a biomembrane bearing a CDδ peptide, as described in claim 27, to a subject in vivo, or to a subject's cells in vitro, in association with a pharmaceutical carrier, in order to inhibit specific immune cells.

33. A therapeutic method for nonspecific immunomodulation and modulating nonimmune cellε comprising the use of a CDδ:ligand conjugate, as described in claim 9, in vivo or in vitro.

34. The method of claim 33 compsiring the use of a CD8:Fcε conjugate, as described in claim 17, to modulate FcεR-bearing cells in vivo or ixi vitro to treat subjects with IgE-mediated allergic disorders.

35. A therapeutic method for the prolongation of cell, tissue and organ graft survival in transplant recipients, compriεing the coating of cells of the graft to be transplanted with membrane-binding CD8 peptides, as deεcribed in claim 1, prior to transplantation into the recipient.

36. A therapeutic method for the prevention of graft-verεus-host disease in bone marrow transplant recipients, comprising pretreating or coadministering donor bone marrow cells with a biomembrane prepara¬ tion, as described in claim 27, that bears both a CD8 peptide and specific host alloantigens, or with a CD8:MHC conjugate, aε deεcribed in claim 10, to inhibit alloreactive immune cells in the donor cell population.